Study of QL1706 before surgery for MSI-H colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy medicine (QL1706) given before surgery to treat colon cancer that hasn't spread yet. It's designed for patients whose tumors have a specific gene feature (MSI-H/dMMR) and who haven't had any prior treatment for this cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colon cancer that hasn't spread to other parts of your body.
- Your tumor is stage IIB or III (T4 or lymph node-positive).
- Your tumor must have a specific gene pattern called MSI-H or dMMR.
- You haven't received any prior cancer treatment for this colon cancer (including surgery, chemo, or immunotherapy).
- You are in good enough health to walk and do daily activities (ECOG score 0 or 1).
- Your kidneys, liver, and blood counts are working well enough (checked by standard tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (QL1706 plus XELOX chemotherapy) given before surgery for stage 3 colon cancer that is MSS/pMMR. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests a new immunotherapy drug (AK104) given before and after surgery for a specific type of colon cancer that is MSI-H or dMMR. The goal is to see if the drug helps shrink the tumor and prevent the cancer from coming back.
This trial tests a combination of two medications, an immunotherapy (QL1706) and a blood-vessel-blocking drug (bevacizumab), for people with a type of colorectal cancer that has a specific genetic feature (MSI-H/dMMR). The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests an experimental drug called QLS1317 for people with advanced solid tumors that have a specific genetic marker (MSI-H or dMMR) and have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new combination of drugs (QL1706 plus chemotherapy SOX) given before and after surgery for stomach or gastroesophageal junction cancer. It aims to shrink the tumor before surgery and help prevent recurrence afterward.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.